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Abstract: Alkaline phosphatase (ALP) has long been considered a marker of hepatobiliary and bone
disorders, but recent studies have shown that increased ALP activity is correlated with various cardio-
metabolic diseases. Thus, we investigated the association of serum ALP level with surrogate markers
of insulin resistance such as triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-
C ratio) and triglyceride and glucose (TyG) index in the general population. The study included
12,868 men and women aged 19 years and older. Participants were categorized into four groups based
on serum ALP level (U/L) as follows: Q1: 55–190 U/L, Q2: 191–224 U/L, Q3: 225–265 U/L, and Q4:
266–923 U/L for men, Q1: 48–161 U/L, Q2: 162–198 U/L, Q3: 199–245 U/L, Q4: 246–790 U/L for
women. The insulin resistance cut-off levels were defined corresponding to the 75th percentile of
the TyG index and TG/HDL-C ratio in the current samples. Odds ratios (ORs) with 95% confidence
intervals (CIs) of insulin resistance according to quartile of serum ALP level were calculated using
weighted multivariate logistic regression analysis. Compared with Q1, the adjusted OR (95% CI) for
insulin resistance of the Q4 serum ALP group was 1.517 (1.234–1.866) in men and 1.881 (1.399–2.528)
in women using the TG/HDL-C ratio and 1.374 (1.093–1.728) in men and 2.047 (1.468–2.855) in women
using the TyG index after adjusting for confounding variables. Serum ALP levels are independently
and positively associated with surrogate markers of insulin resistance in Korean adults.
Keywords: alkaline phosphatase; insulin resistance; triglyceride and glucose index; triglyceride to
high-density lipoprotein cholesterol ratio
1. Introduction
Insulin, which is secreted from pancreatic beta cells, is the main hormone that regu-
lates cellular metabolism in many tissues in human body. Insulin resistance is characterized
by impaired glucose uptake and oxidation, a decrease in glycogen synthesis, and a loss of
function to suppress lipolysis. The clinical importance of insulin resistance has emerged
due to its association with cardio-metabolic diseases, such as type 2 diabetes, cardiovascu-
lar disease (CVD), hypertension, nonalcoholic fatty liver disease (NAFLD), and metabolic
syndrome [1–4]. In particular, insulin resistance plays a key role in the development of
metabolic syndrome. Although the gold standard measurement for assessing insulin
resistance is hyperinsulinemic-euglycemic clamp, it is rarely used in a clinical setting
due to high cost, low accessibility, and low reproducibility [5]. In this context, alternative
indicators of insulin resistance have been documented in previous studies [6–8]. The triglyc-
eride to high-density lipoprotein (HDL)–cholesterol ratio (TG/HDL-C ratio) and triglyc-
eride and glucose (TyG) index are commonly used as alternative markers for assessing
insulin resistance.
Alkaline phosphatases (ALPs) are a group of isozymes catalyzing the hydrolysis of
organic phosphate esters at basic pH [9]. Human ALPs are classified into at least four
isozymes according to specificity of the tissue to be expressed as follows: intestinal alkaline
phosphatase, germ cell ALP, placental ALP, and liver/bone/kidney ALP, which is also
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called tissue-nonspecific ALP (TNSALP) [10]. Various causes can contribute to increase in
serum ALP level, but TNSALP constituted about 90% of the total serum ALP activity [11].
Thus, ALP activity has long been used as a marker of hepatobiliary and bone disorders [12].
However, recent studies have demonstrated that increased ALP activity is related to
various cardio-metabolic diseases [13–17]. Kim et al. showed a positive, independent
association between metabolic syndrome and serum ALP even after adjusting for potential
confounding factors [15]. The link between serum ALP and metabolic syndrome is unclear,
but chronic low-grade inflammation and insulin resistance appear to contribute. In our
previous study, we showed that serum ALP level was positively associated with a high
level of inflammatory markers such as leukocyte count and C-reactive protein in elderly
Koreans [18]. However, little is known about the association between serum ALP level and
biomarkers of insulin resistance. Thus, we investigated the association of serum ALP level
with surrogate markers of insulin resistance such as triglyceride to high-density lipoprotein
cholesterol ratio (TG/HDL-C ratio) and triglyceride and glucose (TyG) index in the general
population using data from the KNHANES dataset.
2. Materials and Methods
2.1. Study Population
This cross-sectional study analyzed data obtained from the Korean National Health
and Nutrition Examination Survey (KNHANES) provided by the Korea Centers for Dis-
ease Control and Prevention (KCDC) from 2009 to 2011. KNHANES is a nationwide,
representative, population-based survey that assesses the nutritional and health status
of Koreans. Data sampling was performed using a stratified, multi-staged, probability
sampling design based on sex, age, and geographical area via household registries. Of the
28,009 participants enrolled in the survey during the study period, we excluded those who
met the following criteria: children and adolescents aged ≤18 years (n = 6531); presence of
osteoporosis; history of cancer, renal, respiratory, rheumatologic, or hepatobiliary disease;
AST ≥ 80 U/L or ALT ≥ 80 U/L; leukocytes ≥10,000/µL; positive urine bilirubin; missing
data of ALP, or history of hormone replacement therapy. After excluding these individuals,
12,868 participants were included in the final analysis (Figure 1). The average age of this
study population was 46.4 years, and the oldest individual was 80 years.
Figure 1. Flowchart of the study population selection.
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2.2. Data Collection
The 2009–2011 KNHANES contained health, nutritional, social, and demographic data
obtained through a three-component survey method. Anthropometric measurements were
measured by trained medical staff following a standardized procedure. Body weight and
height were measured to the nearest 0.1 kg and 0.1 cm, respectively, in light indoor clothing
without shoes. BMI was calculated as weight in kilograms divided by square of height
in meters (kg/m2). SBP and DBP were measured using the patient’s right arm while the
patient was seated and after 10 min of rest, using a standard mercury sphygmomanometer
(Baumanometer, W.A. Baum Co Inc., Copiague, NY, USA). Self-reported cigarette smoking,
alcohol consumption, and physical activity characteristics were collected from question-
naires. Current smoker was defined as a person who currently smokes and who has smoked
more than 100 cigarettes during their lifetime. Ex-smoker was defined as a person who quit
smoking but has smoked more than 100 cigarettes during their lifetime, and non-smoker
was defined as a person who has never smoked. Questions about alcohol intake included
weekly frequency. Regular alcohol consumption was defined as alcohol drinking ≥ twice
per week. The resistance exercise group was defined as those who performed resistance
exercise ≥ three times per week. Educational level was categorized as either elementary
school or below, middle school or below, high school, and college or above. Household
income was classified into four quartiles from lowest to highest. The Homeostatic Model
Assessment for Insulin Resistance (HOMA-IR) value was calculated using the following
formula: fasting plasma glucose (mg/dL) × fasting insulin (µIU/mL). Metabolic syndrome
was defined as the presence of at least three of the following criteria according to the
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III): high
blood pressure (SBP ≥ 130 mmHg or DBP ≥ 85 mmHg); central obesity according to the
Asian-Pacific criteria (waist circumference ≥90 cm for men and ≥80 cm for women); high
fasting glucose (≥100 mg/dL); high TG (≥150 mg/dL); low HDL-cholesterol (<40 mg/dL
for men or <50 mg/dL for women). Individuals who reported taking anti-hypertensive
medication or anti-diabetes medications were considered to have elevated blood pressure
or elevated fasting glucose. Obesity was defined as BMI ≥ 25.0 kg/m2 according to World
Health Organization (WHO) cut-off levels for adult Asians [19]. All blood samples were
obtained from the antecubital vein after a 12 h overnight fast. Fasting plasma glucose
(reference range: 70–99 mg/dL), ALP (reference range: 40–160 U/L), ALT (reference range:
≤35 U/L), AST (reference range: ≤40 U/L), triglyceride (reference range: <150 mg/dL),
and HDL cholesterol levels (reference range: >60 mg/dL) were assessed using a Hitachi
7600 automated chemistry analyzer (Hitachi Co., Tokyo, Japan) with enzymatic assays
following the International Federation of Clinical Chemistry and Laboratory Medicine
(IFCC) recommendation. Leukocyte count was assessed by an automated blood cell counter
(XE-2100D; Sysmex, Kobe, Japan).
2.3. TyG Index
TyG index was defined as
TyG = Ln [fasting triglyceride (mg/dL) × fasting plasma glucose (mg/dL)/2]
2.4. Statistical Analysis
Serum ALP quartiles were categorized as follows: Q1: 55–190 U/L, Q2: 191–224 U/L,
Q3: 225–265 U/L, and Q4: 266–923 U/L for men, Q1: 48–161 U/L, Q2: 162–198 U/L,
Q3: 199–245 U/L, Q4: 246–790 U/L for women. Clinical characteristics of the study
population according to serum ALP quartile were compared using one-way analysis of
variance (ANOVA) or Kruskal–Wallis test for continuous variables according to normality
of distribution and chi-square tests for categorical variables. Results are expressed as mean
and standard deviation (SD) or number (percentage) for quantitative variables. The ORs
(95% CIs) for high TG/HDL ratio and high TyG index were calculated using multiple
logistic regression analysis after adjusting for confounding variables across ALP quartiles.
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To control for type I error, we made the p-value more stringent using bonferroni correction.
Significant p-value for post hoc was determined at p-value < 0.0167. High TG/HDL ratio
and TyG index were defined as those greater than 3.65 and 4.83, respectively, corresponding
to the 75th percentile of the current samples. Proportion of insulin resistance according to
serum ALP quartiles were compared using chi-square tests. All analyses were conducted
using SPSS statistical software (version 25.0; SPSS Inc., Chicago, IL, USA). All statistical
tests were two-tailed, and statistical significance was determined at p-value < 0.05.
2.5. Ethics Statement
The study protocol was reviewed and approved by the Institutional Review Board of
the KCDC and Prevention (IRB No. 2009-01CON-03-2C, 2010-02CON-21-C, 2011-02CON-
06-C). Written informed consent was obtained from all participants when the KNHANES
was conducted, in accordance with the ethical principles of the Declaration of Helsinki.
3. Results
3.1. Clinical Characteristics of the Study Population
The clinical characteristics of the study population according to serum ALP quartile are
presented in Table 1. SBP, DBP, insulin, HOMA-IR, triglycerides, AST, ALT, and white blood
cell (WBC) count significantly increased from the lowest to highest ALP quartiles in both
sexes, but mean age, BMI, fasting plasma glucose, HDL-C significantly increased according
to ALP quartiles only in women. Proportions of individuals with metabolic syndrome
significantly increased according to ALP quartiles in both sexes, but the proportions of
hypertension, impaired fasting glucose, diabetes mellitus, and obesity significantly only
increased in women. Additionally, high household income and high education level were
significantly lowest in the highest ALP quartile.
3.2. Association between TG/HDL Ratio and ALP
Trend analysis of TG/HDL ratio according to ALP quartile in both sexes is shown in
Figure 2. The mean TG/HDL ratio gradually increased with increasing serum ALP quartile
in both men and women (p-value < 0.001).
Figure 2. Trend analysis of TG/HDL ratio according to ALP quartile in both sexes. Values are assessed by ANOVA.
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Table 1. Clinical characteristics of the study population.
Men ALP Quartile (U/L) Women ALP Quartile (U/L)
Q1 (55–190) Q2 (191–224) Q3 (225–265) Q4 (266–923) p-Value Q1 (48–161) Q2 (162–198) Q3 (199–245) Q4 (246–790) p-Value
n 1489 1482 1496 1472 5939 1722 1732 1744 1731 6929
Age (years) 42.2 ± 0.4 42.5 ± 0.4 42.4 ± 0.5 42.9 ± 0.5 0.702 37.4 ± 0.3 39.0 ± 0.4 43.1 ± 0.5 50.4 ± 0.5 <0.001
BMI (kg/m2) 24.0 ± 0.1 24.2 ± 0.1 24.0 ± 0.1 24.2 ± 0.1 0.445 22.1 ± 0.1 22.8 ± 0.1 23.4 ± 0.1 24.3 ± 0.1 <0.001
SBP (mmHg) 120.1 ± 0.5 120.6 ± 0.5 121.4 ± 0.5 122.8 ± 0.5 <0.001 108.6 ± 0.4 111.5 ± 0.4 115.3 ± 0.5 121.7 ± 0.5 <0.001




96.2 ± 0.5 97.6 ± 0.7 97.1 ± 0.6 101.4 ± 1.0 <0.001 89.8 ± 0.3 91.7 ± 0.4 93.3 ± 0.4 99.1 ± 0.7 <0.001
Insulin (µIU/mL)
(2.6–24.9 µIU/mL) 9.8 ± 0.2 10.1 ± 0.2 10.5 ± 0.3 11.1 ± 0.3 0.001 9.3 ± 0.1 10.1 ± 0.2 10.3 ± 0.2 11.1 ± 0.3 <0.001
HOMA-IR 2.4 ± 0.0 2.5 ± 0.1 2.6 ± 0.1 2.8 ± 0.1 0.001 2.1 ± 0.0 2.3 ± 0.0 2.4 ± 0.1 2.9 ± 0.1 <0.001
Triglycerides (mg/dL)
(<150 mg/dL) 142.0 ± 3.9 155.5 ± 4.5 160.6 ± 4.0 170.9 ± 5.2 <0.001 86.1 ± 1.3 99.8 ± 1.8 111.6 ± 2.3 131.3 ± 2.6 <0.001
HDL-C (mg/dL)
(>60 mg/dL) 48.0 ± 0.3 46.3 ± 0.3 45.8 ± 0.3 45.2 ± 0.3 <0.001 53.9 ± 0.4 52.8 ± 0.3 52.0 ± 0.3 49.8 ± 0.4 <0.001
ALT (U/L) (≤35 U/L) 23.3 ± 0.4 25.4 ± 0.5 26.6 ± 0.6 28.6 ± 0.6 <0.001 13.6 ± 0.2 15.0 ± 0.2 17.1 ± 0.3 20.6 ± 0.4 <0.001
AST (U/L) (≤40 U/L) 21.9 ± 0.2 23.0 ± 0.3 23.7 ± 0.3 25.1 ± 0.3 <0.001 17.2 ± 0.1 18.1 ± 0.1 19.5 ± 0.2 22.1 ± 0.3 <0.001
WBC µL
(4000–10000/µL) 6065.5 ± 41.5 6315.2 ± 40.9 6384.0 ± 44.7 6464.6 ± 44.1 <0.001 5455.4 ± 39.4 5636.7 ± 39.8 5777.3 ± 44.1 5866.1 ± 40.6 <0.001
Current smoking (%) 535 (46.2) 561 (45.7) 581 (47.5) 591 (50.1) 0.654 100 (6.7) 76 (5.7) 67 (5.0) 71 (4.6) 0.106
Alcohol drinking (%) 646 (41.7) 572 (37.3) 552 (5.1) 488 (32.5) <0.001 216 (12.7) 199 (12.1) 143 (9.2) 96 (6.4) <0.001
Resistance exercise
(%) 370 (24.0) 294 (19.3) 320 (22.0) 296 (20.2) 0.046 176 (9.6) 136 (7.7) 151 (8.1) 121 (6.4) 0.023
Household income
(%) <0.001 <0.001
Quartile 1 (Lowest) 190 (10.7) 187 (9.6) 241 (13.4) 315 (16.5) 161 (9.3) 234 (13.0) 315 (16.2) 443 (23.4)
Quartile 2 345 (24.5) 361 (25.0) 369 (26.8) 367 (25.4) 412 (25.7) 409 (25.3) 422 (25.7) 464 (27.4)
Quartile 3 424 (29.2) 453 (32.9) 443 (30.6) 407 (30.7) 577 (32.1) 516 (30.1) 512 (31.0) 454 (28.3)
Quartile 4 512 (35.6) 465 (32.5) 428 (29.2) 365 (26.2) 600 (32.8) 570 (31.6) 470 (27.2) 373 (20.9)
Education level (%) <0.001 <0.001
Elementary school 177 (8.1) 202 (9.7) 223 (10.8) 288 (13.0) 118 (6.0) 246 (11.1) 438 (20.0) 757 (38.2)
Middle school 149 (9.9) 159 (8.6) 169 (10.8) 223 (13.0) 120 (7.3) 157 (8.6) 195 (11.4) 210 (13.0)
High school 553 (40.2) 566 (43.2) 529 (41.0) 529 (43.9) 749 (42.5) 725 (44.3) 626 (39.8) 463 (29.9)
≥College 591 (41.8) 532 (38.5) 546 (37.4) 400 (30.2) 757 (44.1) 604 (36.1) 455 (28.8) 286 (18.8)
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Table 1. Cont.
Men ALP Quartile (U/L) Women ALP Quartile (U/L)
Q1 (55–190) Q2 (191–224) Q3 (225–265) Q4 (266–923) p-Value Q1 (48–161) Q2 (162–198) Q3 (199–245) Q4 (246–790) p-Value
Hypertension (%) 293 (14.5) 275 (12.9) 296 (14.2) 311 (15.4) 0.594 92 (4.1) 172 (7.7) 304 (14.1) 491 (24.5) <0.001
Impaired fasting
glucose (%) 398 (23.4) 360 (20.9) 351 (20.9) 364 (22.2) 0.408 172 (9.5) 219 (11.5) 306 (15.1) 389 (21.0) <0.001
Diabetes Mellitus (%) 113 (5.6) 115 (6.2) 97 (4.2) 131 (6.7) <0.001 43 (1.9) 74 (3.2) 97 (4.2) 159 (8.0) <0.001
Obese (%) 170 (20.3) 186 (21.0) 169 (22.0) 194 (24.8) 0.293 86 (15.0) 166 (24.3) 213 (27.4) 330 (35.1) <0.001
Metabolic syndrome
(%) 281 (16.6) 287 (16.5) 317 (18.9) 374 (23.9) <0.001 119 (5.6) 245 (12.1) 358 (17.0) 599 (32.0) <0.001
Abbreviation: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein-cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase;
WBC, white blood cell count. Values are presented as mean ± standard deviation or number (percentage). p-values were assessed by weighted analysis of variance or weighted chi-square test.
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The ORs (95% CIs) for high TG/HDL ratio according to serum ALP quartile are
shown in Table 2. Compared with the lowest quartile, the OR (95% CI) of the highest
ALP quartile for high TG/HDL was 1.517 (1.234–1.866) in men and 1.881 (1.399–2.528) in
women after adjusting for age, sex, BMI, SBP, DBP, AST, ALT, fasting glucose, smoking
status, alcohol consumption, resistance exercise, household income, and educational level
(post hoc p-value < 0.001).
Table 2. Odds ratios and 95% confidence intervals for high TG/HDL ratio according to serum ALP.
ALP Quartile (U/L)
Q1 Q2 Q3 Q4 Overall p-Value
Male
Model 1 Reference 1.250 (1.039–1.503) 1.518 (1.246–1.850) 1.673 (1.384–2.024) <0.001
Model 2 Reference 1.196 (0.990–1.444) 1.425 (1.159–1.750) 1.473 (1.204–1.802) <0.001
Model 3 Reference 1.214 (1.003–1.470) 1.473 (1.195–1.816) 1.517 (1.234–1.866) <0.001
Female
Model 1 Reference 1.483 (1.115–1.972) 1.602 (1.228–2.089) 2.272 (1.720–3.002) <0.001
Model 2 Reference 1.431 (1.073–1.909) 1.517 (1.156–1.991) 1.970 (1.479–2.622) <0.001
Model 3 Reference 1.419 (1.064–1.894) 1.493 (1.133–1.967) 1.881 (1.399–2.528) <0.001
Model 1: age, BMI; Model 2: age, BMI, SBP, DBP, AST, ALT, fasting glucose; Model 3: age, BMI, SBP, DBP, AST, ALT, fasting glucose,
smoking status, alcohol consumption, resistance exercise, household income, and educational level.
3.3. Association between TyG Index and ALP
Figure 3 illustrates the analysis trend for TyG index according to ALP quartile in men
and women. The mean TyG index increased significantly according to serum ALP quartile
in both sexes (p value < 0.001).
Figure 3. Trend analysis of TyG index according to ALP quartile. Values are assessed by ANOVA.
The ORs (95% CIs) for high TyG index according to serum ALP quartile are presented
in Table 3. Compared with the lowest quartile, the OR (95% CI) of the highest ALP quartile
for high TyG index was 1.374 (1.093–1.728) in men and 2.047 (1.468–2.855) in women after
adjusting for age, sex, BMI, SBP, DBP, AST, ALT, fasting glucose, smoking status, alcohol
consumption, resistance exercise, household income, educational level, and menopause
status (post hoc p-value < 0.001).
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Table 3. Odds ratios and 95% confidence intervals for high TyG index according to serum ALP quartile.
ALP Quartile (U/L)
Q1 Q2 Q3 Q4 Overall p-Value
Male
Model 1 Reference 1.151 (0.948–1.396) 1.419 (1.169–1.722) 1.584 (1.290–1.946) <0.001
Model 2 Reference 1.080 (0.873–1.336) 1.353 (1.099–1.665) 1.293 (1.033–1.619) <0.001
Model 3 Reference 1.109 (0.893–1.376) 1.448 (1.168–1.794) 1.374 (1.093–1.728) <0.001
Female
Model 1 Reference 1.658 (1.243–2.210) 1.787 (1.332–2.396) 2.597 (1.953–3.454) <0.001
Model 2 Reference 1.534 (1.127–2.088) 1.667 (1.211–2.296) 2.017 (1.456–2.793) <0.001
Model 3 Reference 1.590 (1.164–2.171) 1.767 (1.284–2.432) 2.047 (1.468–2.855) <0.001
Model 1: age, BMI; Model 2: age, BMI, SBP, DBP, AST, ALT, fasting glucose; Model 3: age, BMI, SBP, DBP, AST, ALT, fasting glucose,
smoking status, alcohol consumption, resistance exercise, household income, and educational level.
4. Discussion
In this nationally representative cross-sectional study, we investigated the association
of serum ALP with insulin resistance in community-dwelling Korean adults. We used
TG/HDL-C ratio and TyG index to assess insulin resistance. Emerging evidence has
identified the TG/HDL-C ratio and TyG index as markers for insulin resistance with
high sensitivity and specificity [6–8]. In the present study, we showed that serum ALP
is positively associated with the TG/HDL-C ratio and TyG index even after adjusting
for potential confounding factors of age, sex, BMI, SBP, DBP, hepatic enzymes, smoking
status, alcohol consumption, resistance exercise, household income, and educational level.
In particular, women showed a stronger association between serum ALP and insulin
resistance surrogates than men. Additionally, HOMA-IR significantly increased according
to ALP quartiles in both men and women.
Previous studies have linked serum ALP and insulin resistance, although the asso-
ciation is still controversial [20–22]. Gurler et al. suggested that there was no significant
difference between ALP levels in 124 female patients with or without insulin resistance [23].
Additionally, several studies reported that there was no significant association between
ALP and incident diabetes [20,24,25]. However, our results are consistent with previous
findings by Kim et al. who showed a significant association between increased ALP levels
and metabolic syndrome [15]. Moreover, among components of metabolic syndrome,
hypertriglyceridemia and low HDL cholesterol were found to be significantly increased
according to ALP levels in 14,224 Korean subjects [22]. Similarly, positive association
for insulin and glucose metabolism with ALP levels were also reported in children and
adolescents [26]. Although the reason for inconsistent results regarding the association
between ALP and insulin resistance is unclear, sex, ethnicity, and study population size
may lead to the discrepancies. Our study and a previous study consistently showed a
stronger relationship between ALP levels and insulin resistance or metabolic syndrome in
women compared to men [15].
ALPs are ubiquitous ectoenzymes, which hydrolyze monophosphate ester. ALPs
have many substrates and participate in various metabolic and biosynthetic pathways [27].
Gene knockout studies have helped define some of functions of each isoenzyme in bone,
teeth, the central nervous system, and in the gut [27]. For example, mice and humans with
inactivated ALPL gene mimic a severe form of hypophosphatasia [28]. Hypophosphatasia
is a rare disorder induced by a mutation in the ALPL gene resulting in a diminished activity
of the enzyme in target tissues. Young infants with hypophosphatasia present various
symptoms ranging from impaired mineralization at birth, bone pain, leg bowing, recurrent
fractures, and muscular insufficiency, to tooth loss in adults [29]. In hypophosphatasia,
three phosphocompounds, including phosphoethanolamine (PEA), inorganic pyrophos-
phate (PPi), and pyridoxal 5’-phosphate (PLP), accumulated endogeneously and appear
to be natural substrates of TNSALP [30,31]. Although PEA remains controversial as an
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endogenous substrate of TNSALP, it is commonly used in the clinics as a diagnostic marker
for hypophosphatasia. Among these substrates, PPi plays a major role in preventing calcifi-
cation; therefore, elevated PPi levels induce skeletal diseases. In order to restore the level
of PPi, ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and progressive
ankyloses protein are involved in the physiological mineralization [32–34]. These proteins
and ALP regulate and finetune the formation of hydroxyapatite crystals, maintaining the
PPi/Pi ratio for normal bone mineralization [35]. Lack of ENPP1 can cause severe depletion
of PPi and arterial calcification in infancy [36]. Additionally, Lomashvile et al. showed
that upregulated TNSALP in rats leads to the hydrolysis and, therefore, inactivation of PPi,
which is a potent inhibitor of hydroxyapatitie crystal growth and a potential inhibitor of
vascular calcification [37].
Elevation of ALP levels are generally associated with cholestatic liver disease, such as
biliary obstruction due to cancer, choledocholithiasis, biliary stricture, sclerosing cholangi-
tis, drug-induced liver injury, and hepatitis. Additionally, bone ALP, which is a marker
of bone formation, is not only involved in physiological but also in pathological miner-
alization, including Paget’s disease, osteogenic sarcoma, healing fracture, osteomalacia,
hyperparathyroidism, hyperthyroidism, chronic kidney disease, and vascular calcifica-
tion [38]. Since various diseases are characterized by high ALP activity, measuring ALP
alone without assessment of other metabolic parameters is insufficient as a surrogate for
insulin resistance. Nonetheless, the results of this study may have clinical implication
because, if the clinician has confirmed that there is no liver or bone-related diseases, insulin
resistance or metabolic syndrome can be considered by seeing elevated ALP levels.
Chronic subclinical inflammation plays an important role in the link between ALP
and metabolic syndrome. Seo et al. reported that inflammatory markers such as C-reactive
protein (CRP) and leukocyte count increased in accordance with serum ALP quartile in
older adults [18]. Additionally, several previous studies have shown that serum ALP level
is positively associated with CRP concentration [39–41]. However, little is known about the
relationship between serum ALP and insulin resistance, another crucial pathophysiology
of metabolic syndrome. Our findings support the idea that insulin resistance contributes to
the association between serum ALP and metabolic syndrome as well as chronic low-grade
inflammation.
The underlying mechanisms for the association between insulin resistance and ALP
remain uncertain, and several possible mechanisms are under consideration. A previous
study reported that serum ALP level is higher in obese people [42]. East Asians generally
have higher body fat percentages than non-Asians at the same BMI. In this regard, our
study population shows a relatively low BMI with high ALP levels. ALP activity has been
shown to be involved in adipogenesis in both experimental and human studies [43,44].
Hernández-Mosqueira et al. found that the gene encoding TNSALP is expressed in adipose
tissue and adipocytes. They found that serum ALP level was inversely associated with
the level of adiponectin, which is closely related to development of type 2 diabetes and
hypertension [44]. Additionally, knocking down the ALPL gene decreased the expression
of leptin, which plays a key role in adipocyte systemic signaling and insulin resistance [45].
These results suggest that an increased TNSALP level contributes to insulin resistance by
increasing leptin level and reducing adiponectin level in a direct or indirect manner. Fur-
thermore, high ALP activity promotes lipolysis, which is associated with insulin resistance
by increased free fatty acids levels [46]. Cheung et al. reported that serum insulin level
was positively associated with bone-specific ALP based on HOMA-IR for pancreatic cell
function in 3773 nondiabetic participants [47]. Another possible mechanism is link between
elevated ALP and low vitamin D. High level of ALP has been reported to reflect decreased
levels of vitamin D in several studies [48,49]. Low vitamin D levels are associated with
smooth muscle cell proliferation, endothelial dysfunction, vascular inflammation, vascular
calcification, and atherosclerosis [50,51].
Conversely, intestinal ALP was reported to prevent induction of metabolic syndrome
by inhibiting uptake of endotoxin (lipopolysaccharides) in high-fat diet-fed mice [52]. How-
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ever, intestinal ALP contributes to only ~10% of total ALP activity in healthy individuals,
thus the results of our findings would not be mainly affected by intestinal ALP activity.
Further studies are required to demonstrate the association between each ALP isozyme
and metabolic syndrome.
This study has several limitations. First, insulin resistance was assessed by surrogate
markers of TyG index and TG/HDL-C ratio instead of the gold standard, hyperinsulinemic-
euglycemic clamp. However, accumulating evidence has validated the sensitivity and
specificity of these indirect markers [6,7]. Previous cross-sectional study also showed
HOMA-IR, which is a representative marker of insulin resistance, increased according to
ALP quartiles in both men and women [15]. Second, since the data were observational and
collected using a cross-sectional design, it is difficult to conclude causation. Although a
large prospective study showed association between ALP and incident type 2 diabetes,
there are a limited number of studies showing a direct link between ALP and insulin
resistance. Therefore, further prospective and experimental studies are required to verify
the direct mechanistic association between insulin resistance and ALP. Third, we measured
total ALP activity for the quantitation according to the recommendation of the Interna-
tional Federation of Clinical Chemistry and Laboratory Medicine. These ALP enzymatic
assays cannot discriminate the ALP isozymes and isoforms, thus we could not conduct
subgroup analysis by each ALP isozyme. Enzyme measurement is also defined as “catalytic
amount”, which is the amount of an agreed-upon substrate that is converted to the product
in an agreed-upon measurement system [53]. The measurement process depends on the
experimental conditions, such as temperature, pH, and the nature of the buffer [54]. There-
fore, serum ALP activity does not reflect the actual ALP concentration. Fourth, this data
does not contain information about serum bilirubin or abdomen ultrasound result, so we
could not exclude the possibility of biliary diseases such as gallbladder stone, cholangitis,
or cholecystitis. To minimize this limitation, we adjusted for the hepatobiliary markers
such as AST and ALT as confounding factors. Despite these potential limitations, our
results offer potential clinical implications. This is the first nationwide, general population
study to show a positive association between serum ALP level and TG/HDL ratio and
TyG index after adjusting for confounding factors. Two previous studies about metabolic
syndrome and ALP showed that low HDL-C and hypertriglyceridemia among components
of metabolic syndrome were significantly associated with ALP [15,22]. Our results are
consistent with these studies. Additionally, compared to TG/HDL ratio or TyG index, ALP
is an economical marker and can be collected regardless of whether the patient was fasting
or not in routine clinical practice. Therefore, our results may have clinical implications
because clinicians may consider insulin resistance or metabolic syndrome by detecting an
elevated ALP levels.
5. Conclusions
In conclusion, serum ALP activity was positively and independently correlated with
TyG index and TG/HDL-C ratio. Since serum ALP level can be affected by various factors,
such as patient’s age, renal, musculoskeletal, and hepatobiliary diseases, ALP cannot be
used alone as an insulin resistance surrogate. Therefore, serum ALP can be used as a
complementary measure in the evaluation of insulin resistance or metabolic syndrome
alongside with TyG index or TG/HDL ratio.
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